EMERYVILLE, Calif., Jan. 15, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq: AMRS ), the industrial bioscience company, today announced the availability of its Pathways Program, a program that provides partners a low-cost, low-risk opportunity to access Amyris’s industry-leading synthetic biology technology. Through the Pathways Program, partners can, with a small initial investment, sponsor and secure a molecule they are interested in having Amyris produce using the next-generation tools and technologies being developed through the company’s recently announced technology investment agreement with the Defense Advanced Research Projects Agency (DARPA). Amyris expects the powerful combination of its existing core technology and bioengineering advancements enabled by its project with DARPA will significantly reduce the time and cost of bringing new molecules to market using industrial biotechnology. The Pathways Program allows partners to access these latest developments and explore bio-synthetic production opportunities with minimal risk and commitment.
Provides Partners a De-Risked Opportunity to Explore Development of New Molecules with a Leader in Synthetic Biology
The Pathways Program provides partners with a de-risked opportunity to use Amyris’s expert capabilities and advanced tools and methodologies for the construction of organisms that convert sugar to the partner’s target molecule. The successful completion of the organism engineering potentially provides a new mode of production with secure stable supply from a renewable resource.
In essence, this program opens up Amyris’s advanced technology platform and leading capabilities to researchers and companies wishing to determine the viability of biological production of target molecules at a lower cost and with minimized risk.
“Our Pathways Program provides partners with a unique and advantaged opportunity to access cutting-edge technologies that are at the forefront of bioengineering to explore the development of new materials with little upfront risk,” said John Melo, President & CEO at Amryis. “Our mission is to accelerate the transition to a world that uses sustainably sourced bio-materials and we believe that making our technology more accessible removes a key barrier to making lower cost, higher performing products for a healthier planet. We have now created several $100-million-dollar supply opportunities for our renewable farnesene technology and expect many more building blocks, like farnesene, to come from opening our platform to the world.”
For partners interested in accessing faster, lower cost to market for sustainable biochemistry please contact Cindy Bryant, Amyris’s Senior Vice President Corporate Development & Collaborations at 510-450-0761 ext. 468.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com .
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as Amyris’s ability to offer molecule development services at low risk and low cost to potential partners and the ability of Amyris technology, existing and under development, to significantly reduce the time and cost of bringing new molecules to market using industrial biotechnology), that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on November 9, 2015. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris and the Amyris logo are registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.
Contacts: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 investor@amyris.com pr@amyris.com
